

Resource Summary Report

Generated by ASWG on Aug 9, 2026

Pacific Blue™ anti-human Lineage Cocktail (CD3, CD14, CD16, CD19, CD20, CD56)

RRID:AB_2889063

Type: Antibody

Proper Citation

BioLegend Cat# 348805, RRID:AB_2889063

Antibody Information

URL: http://antibodyregistry.org/AB_2889063

Proper Citation: BioLegend Cat# 348805, RRID:AB_2889063

Target Antigen: CD3, CD14, CD16, CD19, CD20, CD56

Host Organism: mouse

Clonality: cocktail

Comments: Discontinued: 2021; Applications: FC

Antibody Name: Pacific Blue™ anti-human Lineage Cocktail (CD3, CD14, CD16, CD19, CD20, CD56)

Description: This cocktail targets CD3, CD14, CD16, CD19, CD20, CD56

Target Organism: human

Clone ID: UCHT1, HCD14, 3G8, HIB19, 2H7, HCD56,

Antibody ID: AB_2889063

Vendor: BioLegend

Catalog Number: 348805

Record Creation Time: 20250820T052304+0000

Record Last Update: 20250820T212652+0000

Ratings and Alerts

No rating or validation information has been found for Pacific Blue™ anti-human Lineage Cocktail (CD3, CD14, CD16, CD19, CD20, CD56).

Warning: Discontinued: 2021
Discontinued: 2021; Applications: FC

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Fukasawa K, et al. (2026) Regulatory role of mTORC1 signaling in osteoblasts in acute myeloid leukemia progression and steady-state hematopoiesis. iScience, 29(1), 114533.

Mosialou I, et al. (2025) A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies. Cancer cell, 43(6), 1007.

Kobelski MM, et al. (2024) Evaluation of Osteogenic Phenotype in Postmenopausal Women Receiving Anabolic and Antiresorptive Osteoporosis Therapies. Endocrinology, 165(12).

Wu Z, et al. (2023) Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS. Cell reports. Medicine, 4(8), 101160.

Wang X, et al. (2021) Dysregulated hematopoiesis in bone marrow marks severe COVID-19. Cell discovery, 7(1), 60.